* A study was published in the NEMJ in January 2020. It reported on a clinical trial where 2,860 patients – who had had an ischemic stroke – were assigned to two different LDL-cholesterol targets.
* The paper reported that the patients assigned to the lower LDL-cholesterol target group had a lower event rate during the approximately 3.5 years of follow up.
* There were at least a dozen issues with the study:
1) The trial was industry funded;
2) The authors had extensive conflicts of interest;
3) The trial was registered after it started, not before;
4) The trial was stopped early;
5) The trial measured the intended effects, but not side effects;
6) The LDL-cholesterol targets were not achieved;
7) If the LDL-cholesterol targets were not achieved and benefits occurred, they were the result of something else;
8) The primary end points (the key events to be measured) were changed late in the trial with no reason given;
9) The method of allowing for dropouts favoured the lower LDL-cholesterol target group;
10) Few results were significant or generalisable;
11) The data are due to be shared (only?) with the Cholesterol Treatment Trialists;
12) Issues are present related to conflict and competence – and conspiracy?
* This post goes through each of these issues with the conclusion that the peer review process has failed again.
Last week’s note was about a non-industry-funded study, which examined thousands of people who had had a heart attack or acute heart failure and the relationship between their LDL-cholesterol levels and subsequent mortality. It found consistent relationships between having higher LDL-cholesterol and a lower risk of dying. These findings were supported by examination of all other studies available on the topic (i.e. systematic review).
This week’s note looks at an industry-funded study, which undertook a randomised trial involving 2,860 people who had had an ischemic stroke. It found that those in the lower LDL-cholesterol target group had fewer cardiovascular events than those in the higher LDL-cholesterol target group.
These two papers – albeit one following heart disease and the other following one type of stroke – appear to contradict each other. What’s going on?
The rest of this article is available to Club Members, who get access to all our articles, videos, recipes and newsletters.
To continue reading, please LOGIN or sign up for a membership. Thank you.